Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C

Poynard T, McHutchison JG, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-1313.

Publication Type:

Journal Article

Authors:

Poynard, T.; J G McHutchison; Manns, M.; Trepo, C.; Lindsay, K.; Goodman, Z.; Ling, M.H.; Albrecht, J.

Source:

Gastroenterology, Volume 122, Issue 5, p.1303-1313 (2002)

Keywords:

administration & dosage, Adult, Antiviral Agents, Biopsy, Body Mass Index, drug therapy, Drug Therapy,Combination, France, hepatitis, Hepatitis C, Hepatitis C,Chronic, Human, Inflammation, Interferon Alfa-2b, Liver, Liver Cirrhosis, methods, Necrosis, Odds Ratio, Patients, Polyethylene Glycols, Ribavirin, Support,Non-U.S.Gov't, United States, Viral Load

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/11984517

Export Citation:

RIS Format

Top